Spruce Biosciences, Inc.

SPRB

$57.71

-3.28%

2026-09-03 16:00:00 EDT-$1.96

Healthcare

Biotechnology

NASDAQ

Active Trading

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to ...

Price Action of SPRB

$57.71

-3.28%-$1.96

High—

Low—

52W High-76.0%

Rel. vol—

Interval

Range4.1h

Volume—SMA5SMA10

—

Spruce Biosciences, Inc. (NASDAQ: SPRB) is a biopharmaceutical company headquartered in South San Francisco, California, and founded in 2014. The company specializes in developing and commercializing innovative treatments for rare endocrine conditions with significant unmet medical needs. Its lead product candidate, tildacerfont, is a non-steroidal drug designed to reduce glucocorticoid ...Spruce Biosciences, Inc. (NASDAQ: SPRB) is a biopharmaceutical company headquartered in South San Francisco, California, and founded in 2014. The company specializes in developing and commercializing innovative treatments for rare endocrine conditions with significant unmet medical needs. Its lead product candidate, tildacerfont, is a non-steroidal drug designed to reduce glucocorticoid dependence in patients with congenital adrenal hyperplasia (CAH). Currently, tildacerfont is undergoing Phase 2b clinical trials for adult classic CAH, Phase 2 trials for pediatric classic CAH, and exploratory studies for polycystic ovary syndrome (PCOS). Additionally, Spruce has a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize pharmaceutical substances, expanding its pipeline and research capabilities. The company is led by CEO Javier Szwarcberg, M.D., M.P.H., along with a management team including President and CFO Samir Gharib and Chief Commercial Officer Dale Hooks. As of the latest data, Spruce has 14 full-time employees, reflecting its lean operational structure. Financially, the company is in a pre-revenue stage, with no revenue reported, and has a market capitalization of approximately $127.7 million. Key financial metrics indicate significant research and development investments, with a negative return on equity and negative free cash flow, typical for clinical-stage biotech firms. The company's balance sheet shows a current ratio of 4.67, indicating strong liquidity. Spruce's strategic focus on rare endocrine diseases, coupled with its partnerships and advancing pipeline, positions it to address critical treatment gaps in the market.ExpandCollapse

Founded

2014

Employees

CEO

Javier Szwarcberg

Full Name

Spruce Biosciences, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-123.53%

Market Cap

$0.16B

Current Ratio

9.23

WACC

20.16%

ROIC

-54.63%

Contact Information

https://www.sprucebio.com

415 655 4168

611 Gateway Boulevard, South San Francisco, CA 94080

Key Metrics of SPRB

Snapshot

Latest / TTM · 6 periods

Market Cap

$158.83M

ROCE

-52.0%

EV / EBITDA

-1.44x

+33.0% YoY

FCF Yield

-26.9%

+23.0% YoY

Cash Conversion Cycle

0.0d

Current Ratio

9.23

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of SPRB

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.41x

n/a

Debt / Equity

0.09

n/a

Current Ratio

9.23

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of SPRB

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-5.86 · Revenue $50.00M · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-5.80 · Revenue $3.77M · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-26.93 · Revenue $53.75M · 6 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-5.84 · Revenue $0.00 · 3 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-6.68 · Revenue $0.00
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-8.94 · Revenue $0.00
View filing
Mar 9, 2026
FY2025 · Annual results
EPS $-50.83 · Revenue $0.00
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $-14.58 · Revenue $0.00
View filing
Aug 14, 2025
Q2 FY2025 · Results reported
EPS $-3.41 · Revenue $0.00
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $-24.00 · Revenue $0.00
View filing

Financial Statements of SPRB

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	-100.0%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-39.0M	+26.5%	-32.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-33.3M	+40.4%	-154.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	1.7%	-82.0%	-55.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	5.17x	+78.2%	+97.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$53.0M	+17.3%	+83.1%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-50.83 vs -21.24	-139.3%	-6.68 vs -5.79	-15.4%
Revenue Surprise	$0 vs $2.0M	-100.0%	—	—

Insider Transactions of SPRB

Acquisitions (A)

Since Mar 9, 2026

Disposals (D)

Since Mar 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 27, 2026	Quartel Adrian W	officer: Chief Medical Officer	Restricted Stock Units	A	13,000	—
Jul 27, 2026	Quartel Adrian W	—	—	—	0	—
Jun 30, 2026	Szwarcberg Javier B.	director, officer: CHIEF EXECUTIVE OFFICER	Common Stock	A	266	$4.53
May 21, 2026	SPIEGELMAN DANIEL K	director	Stock Option (Right to Buy)	A	1,700	$52.70
May 21, 2026	SIMPSON CAMILLA V	director	Stock Option (Right to Buy)	A	1,700	$52.70

Leadership Team of SPRB

7 executives

Name	Title	Compensation	Gender	Year Born	Status
Javier Szwarcberg	Chief Executive Officer & Director	USD 1,118,250	—	1970	Active
Samir Gharib	President & Chief Financial Officer	USD 784,043	Male	1982	Active
Kirk Ways	Chief Medical Officer & Director	USD 596,833	—	1953	Active
Michael G. Grey	Executive Chairman	USD 70,000	Male	1953	Active
Daven Mody	Senior Vice President of Regulatory & Quality	—	—	—	Active
Corwin Dale Hooks	Chief Commercial Officer	—	Male	1967	Active
Bruno Gagnon BPHARM	Senior Vice President of Clinical Development Operations	—	Male	1969	Active

Recent News of SPRB

GuruFocus8/26/2026Neutral

Spruce Biosciences Announces Launch of MPS3BStudy.com

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor

Business Wire8/26/2026Neutral

Spruce Biosciences Announces Launch of MPS3BStudy.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn about, and register their interest in, t.

Business Wire8/24/2026Neutral

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanf.

GuruFocus8/12/2026Neutral

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord

Business Wire8/12/2026Neutral

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was a period of significant execution as we advanced TA-ERT toward our planned BLA submission in the fourth quarter, which.

Historical Employee Count of SPRB

Current

Change

-61.90%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	8	10-K	Mar 9, 2026	View
Dec 31, 2024	21	10-K	Apr 15, 2025	View
Dec 31, 2023	29	10-K	Mar 18, 2024	View
Dec 31, 2022	27	10-K	Mar 16, 2023	View
Dec 31, 2021	15	10-K	Mar 14, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Spruce Biosciences, Inc.